Based in Jersey, Diabetology Ltd has a research centre in London,administration in Surrey,pre clinical JV in China & a European clinical & business development centre in Savoie, France.

With key personnel in Research, Clinical Development and Commercial functions, we are fully committed to taking our own research into clinical human studies, and beyond.

Our philosophy is to form collaborations & partnerships to further key projects, and to outsource many non-core activities. Thus we are able to keep overheads low, conserving shareholder's resources.

Diabetology is a privately funded company.

Key Projects:

1 Axcess Oral Insulin - 

• Commonly employed enteric coating techniques can safely shuttle insulin past the stomach and deliver much of an oral dose intact to the small intestine

• The Company has identified classes of compounds that appear to facilitate insulin absorption in the small intestine adequately to meet clinical and commercial objectives, and that are already used for completely different purposes as excipients in pharmaceutical formulations

• Use of such agents in its third-generation Axcess delivery technology thereby obviates one major aspect of regulatory risk -- the risk of toxicity with novel facilitator agents or carriers -- while also potentially reducing development timelines by eliminating the need for certain preparatory toxicology studies.

• Use of such agents for oral peptide delivery is novel and, the Company believes, patentable; the Company has exclusive licenses in the field of diabetes to a series of patent applications covering Axcess delivery technology

• Finally, the Company believes that its readily available facilitator compounds may endow it with cost advantages over competing oral insulin delivery systems that seek to employ novel absorption facilitators or carriers.

2 Type II Diabetes Therapy:

The Company is in discussions with manufacturers of oral insulin sensitizing agents of the thiazolidinedione (glitazone) class to combine such an agent with insulin in a single tablet. Thiazolidinediones stimulate muscle uptake of glucose and reduce endogenous glucose production, mechanisms that complement insulin's. They are also one of the mainstays in the treatment of Type II diabetes.

3 Diabetes Vaccine:

The Company is in the early stages of developing an oral vaccine to delay or prevent the onset of Type II diabetes. Utilizing its proprietary Vaxcine technology, the Company is developing an approach to tolerize the immune system to GAD (glutamic acid decarboxylase), a molecule found on the surface of pancreatic β islet cells that stimulates the production of anti-GAD autoantibodies, thereby causing β islet cell destruction. The presence of anti-GAD antibodies in Type II diabetics correlates strongly with the later development of insulin dependence. Preclinical testing demonstrates that the Company's vaccine candidate can delay the onset of diabetes in a mouse model of diabetes, the non-obese diabetic, or NOD, mouse.

4 Novel Diabetes Peptide/Protein Therapeutics

Novel Glucose uptake peptide regulators

Small Peptide Insulin Mimetics

The Company is utilizing its proprietary Mozaic combinatorial screening technology to identify potential peptide therapeutics for diabetes. Mozaic enables the rapid screening of entirely novel peptides, and peptide-like compounds both in vitro and in whole-cell assay systems.

5 Stem Cell Therapies:

The Company intends to employ Mozaic technology to establish reliable methods for forcing pluripotent stem cells to differentiate into functioning β islet cells. The power of Mozaic in this application is its capacity to test millions of peptide-like compounds as differentiation ligands. The Company is working with several groups to gain access to suitable sources of pluripotent stem cells.